{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:30:15Z","timestamp":1786437015905,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,16]]},"abstract":"<jats:p>\n                    Risk factors for venous thromboembolism (VTE) and survival is not known in elderly patients with chronic myeloid leukemia (CML). To examine risk factors for VTE and survival in elderly patients with CML. We used the United States Surveillance, Epidemiology, and End Results and Medicare database for CML patients \u226565 years. VTE was defined as deep vein thrombosis or pulmonary embolism. Logistic regression was used to examine the risk factors for VTE and Cox proportional regression was used to evaluate the effect of VTE on mortality and survival. Among 5535 elderly patients diagnosed with CML (2000\u20132015), 11.4% of had a diagnosis of VTE. Patients &lt;75 years of age and females had a higher risk of VTE, and Asian patients had a lower risk of VTE. Comorbidities associated with VTE were anemia (adjusted odds ratio [OR\n                    <jats:sub>a<\/jats:sub>\n                    ]\u2005=\u20051.89, 95% confidence interval [CI], 1.48\u20132.41), hypertension (OR\n                    <jats:sub>a<\/jats:sub>\n                    \u2005=\u20051.88, 95% CI, 1.43\u20132.49), heart failure (OR\n                    <jats:sub>a<\/jats:sub>\n                    \u2005=\u20051.70, 95% CI, 1.40\u20132.07), obesity (OR\n                    <jats:sub>a<\/jats:sub>\n                    \u2005=\u20051.44, 95% CI, 1.15\u20131.80) and kidney disease (OR\n                    <jats:sub>a<\/jats:sub>\n                    \u2005=\u20051.32, 95% CI, 1.09\u20131.59). VTE was a predictor of death in patients &lt;75 years of age but not in the overall population. Data were stratified into 3 treatment groups: tyrosine kinase inhibitors (TKIs), chemotherapy and no treatment (no TKI and no chemotherapy) groups. Among 3085 elderly patients with CML (2007\u20132015), risk of death was higher in patients who received chemotherapy. Overall survival was longer in patients who received TKI (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001); however, VTE was a predictor of death in the TKI group. Our findings may help to determine the VTE risk profile and impact on survival in elderly patients with CML.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000042412","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T14:02:06Z","timestamp":1747836126000},"page":"e42412","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Risk factors associated with venous thromboembolism and impact on survival in the elderly US population with chronic myeloid leukemia"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8766-1797","authenticated-orcid":false,"given":"Ambarina S.","family":"Faiz","sequence":"first","affiliation":[{"name":"Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Sridharan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Rutgers School of Public Health, Piscataway, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire S.","family":"Philipp","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260811","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaccao.2021.03.001","article-title":"Venous and arterial thromboembolism in patients with cancer: JACC: CardioOncology state-of-the-art review.","volume":"3","author":"Gervaso","year":"2021","journal-title":"JACC CardioOncol"},{"key":"R2-20260811","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1538-7836.2006.01804.x","article-title":"Incidence of venous thrombosis in a large cohort of 66329 cancer patients: results of a record linkage study.","volume":"4","author":"Blom","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R3-20260811","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/jth.14475","article-title":"Risk of thromboembolic and bleeding outcomes following hematological cancers: a Danish population-based cohort study.","volume":"17","author":"Adelborg","year":"2019","journal-title":"J Thromb Haemost"},{"key":"R4-20260811","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.blre.2018.06.002","article-title":"Venous thromboembolism incidence in hematologic malignancies.","volume":"33","author":"Kekre","year":"2019","journal-title":"Blood Rev"},{"key":"R5-20260811","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1182\/blood-2008-08-175745","article-title":"Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival.","volume":"113","author":"Ku","year":"2009","journal-title":"Blood"},{"key":"R6-20260811","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/cam4.332","article-title":"A Retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center.","volume":"4","author":"Vu","year":"2015","journal-title":"Cancer Med"},{"key":"R7-20260811","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.leukres.2010.11.011","article-title":"Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism.","volume":"35","author":"Whittle","year":"2011","journal-title":"Leuk Res"},{"key":"R8-20260811","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.thromres.2015.05.010","article-title":"Venous thromboembolism in patients with chronic lymphocytic leukemia.","volume":"136","author":"\u0160imkovi\u010d","year":"2015","journal-title":"Thromb Res"},{"key":"R9-20260811"},{"key":"R10-20260811","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1182\/bloodadvances.2018018614","article-title":"Imatinib is still recommended for frontline therapy for CML.","volume":"2","author":"Hantel","year":"2018","journal-title":"Blood Adv"},{"key":"R11-20260811","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long\u2010term outcomes of imatinib treatment for chronic myeloid leukemia.","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"R12-20260811","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1038\/s41375-020-0902-1","article-title":"Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989\u20132017.","volume":"34","author":"Ector","year":"2020","journal-title":"Leukemia"},{"key":"R13-20260811","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MBC.0000000000001226","article-title":"Venous thromboembolism and acute myeloid leukemia: risk factors and mortality in elderly White, Black and Asian patients.","volume":"34","author":"Faiz","year":"2023","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R14-20260811","first-page":"345","article-title":"Risk factors and mortality associated with venous thromboembolism in the elderly US Population with acute lymphocytic leukemia.","volume":"34","author":"Faiz","year":"2024","journal-title":"Thromb Update"},{"key":"R15-20260811","doi-asserted-by":"crossref","first-page":"107585","DOI":"10.1016\/j.leukres.2024.107585","article-title":"Risk factors and mortality associated with venous thromboembolism in the elderly US population with chronic lymphocytic leukemia.","volume":"146","author":"Faiz","year":"2024","journal-title":"Leuk Res"},{"key":"R16-20260811","article-title":"Surveillance Research Program, National Cancer Institute;"},{"key":"R17-20260811","first-page":"IV","article-title":"Overview of the SEER-medicare data: content, research applications, and generalizability to the United States elderly population.","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"R18-20260811","first-page":"508","article-title":"Racial differences in four leukemia subtypes: comprehensive descriptive epidemiology.","volume":"8","author":"Zhao","year":"2018","journal-title":"Sci Rep"},{"key":"R19-20260811","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1479-5876-5-23","article-title":"CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia.","volume":"5","author":"Pulte","year":"2007","journal-title":"J Transl Med"},{"key":"R20-20260811","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"R21-20260811","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/pds.2341","article-title":"A systemic review of validating methods for identifying venous thromboembolism using administrative and claims data.","volume":"21","author":"Tamariz","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R22-20260811","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.thromres.2016.11.015","article-title":"Venous thromboembolism incidence, recurrence, and mortality based on women\u2019s health initiative data and medicare claims.","volume":"150","author":"Burwen","year":"2017","journal-title":"Thromb Res"},{"key":"R23-20260811","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"R24-20260811","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41598-017-01307-0","article-title":"Leukemia and risk of venous thromboembolism: a meta-analysis and systematic review of 144 studies comprising 162,126 patients.","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"R25-20260811","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/cam4.1461","article-title":"Incidence and survival of hematological cancers among adults ages \u226575 years.","volume":"7","author":"Krok-Schoen","year":"2018","journal-title":"Cancer Med"},{"key":"R26-20260811","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1080\/10428194.2018.1538505","article-title":"Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL.","volume":"60","author":"Kim","year":"2019","journal-title":"Leuk Lymph"},{"key":"R27-20260811","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population.","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"R28-20260811","doi-asserted-by":"crossref","first-page":"e0220864","DOI":"10.1371\/journal.pone.0220864","article-title":"Racial\/ethnic, age and sex disparities in leukemia survival among adults in the United States during 1973-2014 period.","volume":"14","author":"Utuama","year":"2019","journal-title":"PLoS One"},{"key":"R29-20260811"},{"key":"R30-20260811","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","article-title":"Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008.","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J Clin Oncol"},{"key":"R31-20260811","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","article-title":"Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.","volume":"122","author":"Hoglund","year":"2013","journal-title":"Blood"},{"key":"R32-20260811","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study.","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:01:32Z","timestamp":1786435292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":32,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042412","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]}}}